1-8 of 8
Stephan Ruetz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Grainne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortes-Cros, Stephan Ruetz, Therese-Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (21): 6257–6267.
https://doi.org/10.1158/0008-5472.CAN-18-0338
Published: 01 November 2018
View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
Open the PDF for Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 in another window
Includes: Supplementary data
Journal Articles

Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Sébastien Jeay, Patrick Chène, Stéphane Ferretti, Pascal Furet, Bjoern Gruenenfelder, Vito Guagnano, Nelson Guerreiro, Ensar Halilovic, Francesco Hofmann, Joerg Kallen, Michelle Léonard, Robert Mah, Keiichi Masuya, Rita Ramos, Caroline Rynn, Stephan Ruetz, Thérèse Stachyra-Valat, Stefan Stutz, Andrea Vaupel, Jens Wuerthner, Philipp Holzer
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1225.
https://doi.org/10.1158/1538-7445.AM2016-1225
Published: 15 July 2016
View article titled, Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2
Journal Articles

Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics

Philipp Holzer, Patrick Chène, Stéphane Ferretti, Pascal Furet, Tobias Gabriel, Bjoern Gruenenfelder, Vito Guagnano, Francesco Hofmann, Joerg Kallen, Robert Mah, Keiichi Masuya, Rita Ramos, Stephan Ruetz, Caroline Rynn, Thérèse Stachyra-Valat, Stefan Stutz, Andrea Vaupel, Sébastien Jeay.
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4855.
https://doi.org/10.1158/1538-7445.AM2016-4855
Published: 15 July 2016
View article titled, Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics
Journal Articles

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Sebastien Jeay, Swann Gaulis, Stéphane Ferretti, Geneviève Albrecht, Louise Barys, Daniel Guthy, Ensar Halilovic, Moriko Ito, Masato Murakami, Astrid Pornon, Stephan Ruetz, Kavitha Venkatesan, Jianjun Yu, Michael Jensen, Marion Wiesmann, Jens Wuerthner, Diana Graus-Porta
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2909.
https://doi.org/10.1158/1538-7445.AM2014-2909
Published: 01 October 2014
View article titled, Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models
Journal Articles

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Sebastien Jeay, Joerg Berghausen, Nicole Buschmann, Patrick Chène, Robert Cozens, Dirk Erdmann, Stéphane Ferretti, Pascal Furet, Tobias Gabriel, François Gessier, Diana Graus-Porta, Francesco Hofmann, Philipp Holzer, Moriko Ito, Edgar Jacoby, Michael Jensen, Joerg Kallen, Marc Lang, Joanna Lisztwan, Masato Murakami, Carole Pissot-Soldermann, Stephan Ruetz, Caroline Rynn, Dario Sterker, Stefan Stutz, Thérèse Valat, Marion Wiesmann, Keiichi Masuya
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1797.
https://doi.org/10.1158/1538-7445.AM2014-1797
Published: 01 October 2014
View article titled, Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial
Journal Articles

Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor

Keiichi Masuya, Pascal Furet, Stefan Stutz, Philipp Holzer, Carole Pissot-Soldmann, Nicole Buschmann, Thérèse Valat, Stéphane Ferretti, Stephan Ruetz, Caroline Rynn, Joerg Berghausen, Edgar Jacoby, Marc Lang, Tobias Gabriel, Francesco Hofmann, Joerg Kallen, Sébastien Jeay, Francois Gessier
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): DDT01-01.
https://doi.org/10.1158/1538-7445.AM2014-DDT01-01
Published: 01 October 2014
View article titled, Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor
Journal Articles

Abstract #4677: NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity

Andrew Massey, Paul Brough, Michael Jensen, Stephan Ruetz, Joseph Schoepfer, Paul Workman, Carlos Garcia-Echeverria, Martin Drysdale
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4677.
Published: 01 May 2009
View article titled, Abstract #4677: NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity
Journal Articles

Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series

Frederic Stauffer, Carlos Garcia-Echeverria, Pascal Furet, Christian Schnell, Stephan Ruetz, Michel Maira, Christine FRITSCH
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 269.
Published: 01 May 2007
View article titled, Biochemical, cellular and in vivo profiling of a new PI3K inhibitor from the imidazoquinoline series